Zoladex

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Zoladex with TGC MR SGM - 07/2021.

Exception Criteria Questions:

A. Is the product being requested for the treatment of prostate cancer?
❑ Yes ❑ No *If No, skip to Clinical Criteria Questions*

B. The preferred products for your patient's health plan are Eligard and Firmagon. Can the patient's treatment be switched to a preferred product?
If Yes, please obtain Form for preferred product and submit for corresponding PA. ❑ Yes ❑ No

C. Does the patient have a documented hypersensitivity to both of the preferred products (Eligard and Firmagon)?
ACTION REQUIRED: If Yes, please attach supporting chart note(s). ❑ Yes ❑ No

Clinical Criteria Questions:

1. What is the diagnosis?
❑ Prostate cancer
❑ Breast cancer
❑ Dysfunctional uterine bleeding (use as an endometrial thinning agent) (3.6 mg dose only)
❑ Chronic anovulatory uterine bleeding (use as an endometrial thinning agent) (3.6 mg dose only)
❑ Preservation of ovarian function (3.6 mg dose only)
❑ Prevention of recurrent menstrual related attacks in acute porphyria (3.6 mg dose only)
❑ Uterine leiomyomata (fibroids) (3.6 mg dose only)
❑ Endometriosis (3.6 mg dose only)
❑ Gender dysphoria
❑ Other _____

2. What is the ICD-10 code? _____

3. What dose of Zoladex is being prescribed?
❑ Zoladex 3.6 mg
❑ Zoladex 10.8 mg *Skip to #8*

4. Is this a request for continuation of therapy with Zoladex 3.6 mg? ❑ Yes ❑ No *If No, Skip to diagnosis section*

5. *If the diagnosis is Preservation of ovarian function*, is the patient premenopausal and still undergoing chemotherapy? ❑ Yes ❑ No *No further questions*

6. *For all other diagnosis besides Gender dysphoria or preservation of ovarian function,* has the patient experienced clinical benefit while receiving the requested drug? ❑ Yes ❑ No
For gender dysphoria, skip to diagnosis section

7. Has the patient experienced an unacceptable toxicity while receiving the requested drug? ❑ Yes ❑ No *No further questions*

8. Is this a request for continuation of therapy with Zoladex 10.8 mg? ❑ Yes ❑ No *If No, Skip to diagnosis section*

9. Does the patient have a diagnosis of gender dysphoria? *If Yes, skip to diagnosis section* ❑ Yes ❑ No

10. Has the patient experienced clinical benefit while receiving the requested drug? ❑ Yes ❑ No

11. Has the patient experienced an unacceptable toxicity while receiving the requested drug? ❑ Yes ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Breast Cancer

12. What is the patient's hormone receptor (HR) status? ***ACTION REQUIRED: Attach hormone receptor testing results.***
❑ HR-Positive ❑ HR-Negative ❑ Unknown

Section B: Endometrial thinning agent (3.6 mg dose only)

13. Will Zoladex 3.6 mg be used as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding? *If Yes, no further questions* ❑ Yes ❑ No

14. Will Zoladex 3.6 mg be used for treatment of chronic anovulatory uterine bleeding in a patient with severe anemia?
❑ Yes ❑ No

Section C: Endometriosis (3.6 mg dose only)

15. For how many months has the patient already received Zoladex 3.6 mg for this indication? _____ months

Section D: Uterine leiomyomata (fibroids)

16. Will Zoladex 3.6 mg be given prior to surgery? ❑ Yes ❑ No

Section E: Preservation of ovarian function

17. Is the patient premenopausal and undergoing chemotherapy? ❑ Yes ❑ No

Section F: Gender Dysphoria

18. Is Zoladex being prescribed for pubertal hormonal suppression in an adolescent patient? ❑ Yes ❑ No
If No, skip to #20
19. Which Tanner Stage of puberty has the patient reached?
❑ I ❑ II ❑ III ❑ IV ❑ V ❑ Unknown *No further questions*

20. Is the patient undergoing gender transition? ❑ Yes ❑ No

21. Will the patient receive Zoladex concomitantly with gender-affirming hormones? ❑ Yes ❑ No

Section G: Prevention of recurrent menstrual related attacks in acute porphyria

22. Is Zoladex being requested to prevent recurrent menstrual related attacks in acute porphyria? ❑ Yes ❑ No

23. Is Zoladex being prescribed by, or in consultation with, a physician experienced in the management of porphyrias?
❑ Yes ❑ No

Step Therapy Override: Complete if Applicable for the state of Maryland.	Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?	Yes	No
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No

Step Therapy Override: Complete if Applicable for the state of Virginia.	Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No
Is the preferred drug contraindicated?	Yes	No
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720